J Cancer 2018; 9(10):1731-1736. doi:10.7150/jca.24785
Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires
1. Orthopaedic Department, “Limassol” General Hospital, Cyprus
2. 1st Orthopaedic Surgery Department, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Greece
3. Department of Orthopaedic Surgery, “G. Papageorgiou” General Hospital, Aristotle University of Thessaloniki, Greece
4. 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
5. Anesthesiology Department, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
6. Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China
7. Department of Respiratory Diseases, The Affiliated Jiangning hospital of Nanjing Medical University, Nanjing, China
8. Scientific co-operator of Immunology - Histocompatibility Laboratory of “G. Papageorgiou” General Hospital, Thessaloniki Greece
9. Pulmonary-Oncology Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece
10. Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
11. Thoracic Surgery Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
12. Surgery Department (NHS), University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
13. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Greece
14. Ear, Nose and Throat Department, “Saint Luke” Private Hospital, Thessaloniki, Panorama, Greece
15. Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China
*These authors contributed equally to this work.
Tremmas I, Petsatodis G, Potoupnis M, Laskou S, Giannakidis D, Mantalovas S, Koulouris C, Katsaounis A, Pavlidis E, Amaniti A, Huang H, Bai C, Shi D, Dardas A, Zarogoulidis P, Sardeli C, Konstantinou F, Katsikogiannis N, Zarogoulidis K, Karapantzos I, Karapantzou C, Shen X, Kesisoglou I, Sapalidis K. Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires. J Cancer 2018; 9(10):1731-1736. doi:10.7150/jca.24785. Available from http://www.jcancer.org/v09p1731.htm
Background: Due to the severity of the primary disease in patients with lung cancer, quality of life (QoL) is often overlooked. Factors that form QoL should be taken in consideration when planning the appropriate treatment and determining therapy targets, because of the increasing frequency of bone metastasis leading to high levels of pain. Purpose of this study is to assess quality of life in patients with lung cancer, before and after treatment combined with zoledronic acid.
Methods and materials: QoL was assessed in 80 patients (49 males-31 females), of which 45 developed bone metastasis. Prior and post treatment (with co administration of zoledronic acid) seven reliable scales: Pittsburgh Sleep Quality index (PSQI), Epworth Sleeping Scale (ess), Dyspnea Scale (ds), Fatigue Severity Scale (FSS), Brief Pain Inventory (BPI), Fact-G scale for sleep quality and EQ-5D for general health condition.
Results: Statistically positive correlations were verified between PSQI-DS, PSQI-FSS, BPI-ESS, DS-FSS, DS-BPI and BPI-FSS (p<0,005) prior and post treatment. Patients sleep quality was improved, pain levels decreased and betterment in quality of life was marked (p<0,001). Although significant decrease in fatigue levels was observed (p<0,001) there has been an increase in dyspnea symptoms (p<0,001).
Conclusions: Significant improvement was apparent when zoledronic acid was co administered in any treatment in patients with lung cancer. Sleep quality, fatigue and pain parameters also improved, with no positive impact on the symptoms of dyspnea.
Keywords: sleep quality, lung cancer, bone metastasis, zoledronic acid
Quality of life is a factor that consists of many parameters and unfortunately, its importance is overlooked in severe diseases like lung cancer, due to the primary disease and the adjacent symptoms. In cases where conservative (symptomatic) treatment does not prolong life expectancy, like lung cancer, our main concern is to improve the QoL and relief patients from their symptoms as many of them are elderly with complex medical history and high rates of morbidity. Symptoms in patients with cancer regardless type, classification and treatment are persistent and cause fatigue to any individual. In particular, pain and fatigue represent two of the most important issues of a cancer patient with the latter affecting both the way of life and psychological condition, interfering with daily functionality. Limitations to daily activities combined with severity of the disease can often lead to depression, which is often overlooked. Data from clinical studies show that there is a strong correlation between lung cancer and bad psychological state, anxiety and depression [5, 6] even after three months from the initial diagnosis. Although pain is the main issue for the vast majority of the patients, it is also inadequately treated in up to 55% of the cases under palliative treatment.
Bone metastasis are common in advanced stages of the disease, reaching 70-80% in breast and prostate cancer and 40%in lung cancer. Pathological fractures, bone surgery and spinal cord compression events (Skeletal Related Events-SREs) are the most common causes of pain in cancer patients influencing mobility, functionality, social life and quality of life. Approximately 2/3 of the patients with bone metastasis develop pain, which in 50% of the cases ranges from moderate to severe. In a relevant meta-analysis it was found that SREs increase the need of strong opioids for pain management. In addition, patients that have developed even one SRE during their course of life are at a higher risk of developing new with a great impact on their life expectancy. Pain in cancer patients affects not only the quality of life, but also the ability to work, mobilize and interact with others, resulting in bad psychological condition with frequent sleep disorders leading to a vicious circle.[15, 16]
Combination of opioids and radiotherapy could prove effective in pain relief in patients with metastatic bone disease , but frequent visits to the hospital and tolerance in drugs should be taken in consideration to evaluate QoL. Bone targeted therapies like bisphosphonate and denosumab show high specialty in treating skeletal events and pain due to metastasis. They are administered to patients with mild pain in order to treat, or prevent, bone metastasis, reducing the need of strong opioids. In a clinical study that compared the efficiency of clodronic to zoledronic acid in patients with metastatic prostate cancer, the latter showed better results in relieving the pain. It has been proven that administrating zoledronic acid with radiotherapy shows better results in preventing bone metastasis, reducing pain levels and improving QoL than radiotherapy as a sole treatment. The specific treatment for each patient and early administration is crucial for pain management and reduction of the exhausting effects of metastatic bone pain.
The purpose of this study is to assess the quality of life in patients with primary lung cancer, with and without bone metastasis, with the use of seven reliable scales.
This prospective study included 80 patients, with and without bone metastasis, with primary lung cancer. Each was questioned before and after treatment with co administration of zoledronic acid. Age varies from 43 to 69 years with average 54 years. 49 of the participant were male and 31 female of which 43.8% (26m and 9f) showed no bone metastasis and 56.2% (23m and 22f) had metastatic bone disease. All patients suffered from non-small cell lung cancer (NSCLC). Histological distribution was 46.1% adenocarcinoma, 38.4% squamous and 15.3% large cell carcinoma.
Patients were referred for treatment at the Pulmonary Department-Oncology Unit at G. Papanikolaou University Hospital of Thessaloniki over a period of 24 months and interviewed in the order of their arrival. Moreover it was conducted according to the World Medical Association Declaration of Helsinki. In order to show variations in sleep quality, severity of symptoms of fatigue and pain, quality of life and general condition of patients health we used t test for paired samples. Furthermore, we used correlation techniques and more specific the Pearson correlation. Table 1.
|Seven reliable scales were used:|
|(1) PSQI (Pittsburgh Sleep Quality Index)|
|(2) ESS (Epworth Sleeping Scale)|
|(3) DS (Dyspnea Scale)|
|(4) FSS (Fatigue Severity Scale)|
|(5) BPI (Brief Pain Inventory)|
|(6) FACT-G (Functional Assessment of Cancer Therapy - General Scale)|
|(7) EQ-5D (European Quality of Life-5 Dimensions Scale)|
Pittsburgh Sleep Quality Index (PSQI) is an effective tool to assess quality and patterns of sleep in adults, by differentiating good from bad sleep. This is achieved by measuring seven parameters (sleep latency, subjective sleep quality, duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the past month). Scoring is on a 0 to 3 scale with 3 reflecting bad sleep quality. PSQI has a high diagnostic sensitivity and specificity distinguishing bad from good sleep. The scale has been applied to patients with malignancy  and lung cancer , although it is not yet clear if QoL in these patients is affected because of the pain or psychological disorders.
Epworth Sleeping Scale (ESS) is a simple and valid, which is used to estimate the patients average sleep propensity in daily life. It is a self-administered questionnaire. Patients are requested to rate on a scale from 0 to 3 their usual chances of dozing off or falling asleep while engaged in eight different activities(sitting and reading, watching TV, sitting inactive in a public place, as a passenger in a car for at least one hour, lying down in the afternoon to rest, sitting and talking to someone, sitting quietly after a lunch without any alcohol, in a car while stopped for a few minutes in traffic). ESS has shown good results combined either with other scales, or on patients with primary and metastatic brain cancer  and lung cancer.
Dyspnea Scale (DS) is a five-question scale that describes the entire range of respiratory disability and it is completed by either the patient or the physian in the form of an interview. Its main purpose is to quantify the disability associated with breathlessness by identifying that it occurs when it should not. It correlates well with other lung function measurements to provide a better view of the patients' health.
The Fatigue Severity Scale (FSS) is a nine-item scale, which measures the severity of fatigue and its effect on a person's activities and social life. It was initially designed for patients with multiple sclerosis and lupus but gradually  found application in a variety of disorders that cause fatigue proving its reliability. Fatigue in these patients is related to psychological disorders, pain and dyspnea.
The Brief Pain Inventory (BPI) evaluates the intensity, quality, relief and interference of pain in cancer patients. It is a self-administered questionnaire that handles intensity of the pain and the degree to which it interferes with the patients daily activities. It is reliable and highly sensitive in estimating the alternation in intensity and the effect of pain. With BPI we can examine a wide range of pain as the patient is required to provide information on the intensity of pain during the past week and on time of examination, on a scale from 0 to 10 while also a contour of a human body is provided to pin point the exact origin of pain. BPI reflects quantitatively and qualitatively the effects of pain making it a useful tool applied on clinical and epidemiological studies in global scale.
The Functional Assessment of Cancer Therapy - General Scale (FACT-G) is a most useful tool that helps to evaluate QoL in patients that undergo treatment for cancer, by evaluating the effect of the certain treatment in four fields-physical, social/family, emotional, functional. It consists of 27 questions, each rates from 0 to 4, with the higher score representing better quality of life. Studies proved that FACT-G is the best tool in assessing QoL in cancer patients, but also combined with other variables (histological type, gender, weight loss) offers prognostic value for the patients' course.
Finally, the European Quality of Life-5 Dimensions Scale (EQ-5D) is a general health condition measurement scale applied in a variety of cases and is composed of two parts with the first covering five fields (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each field has 5 levels. The second (EQ VAS) records the patients' health on a vertical scales cored from 0 to 100, where 100 represents the best imaginable health state and 0 the worst at the time it is completed. The scale has been applied to cancer patients with high specificity.
The significant statistical correlation between the results of the scales used in patients before treatment was assessed. There was a statistically significant correlation between PSQI and DS(r=0,279, p=0,012) and FSSN (r=0,263, p-0,018) signifying that low sleep quality is related to high levels of fatigue and dyspnea. In addition, the higher the level of experienced pain, the higher the levels of sleepiness and vice versa (r=0,259, p=0,020). High statistical correlation was indicated between the severity of dyspnea and fatigue (r=0,845, p<0,001), and severe dyspnea was associated with high levels of pain (r=0.310, p=0,005). Further comparison showed that high levels of pain show high levels of fatigue (r=0,416, p<0,001), with a negative result in fatigue levels regarding patients' general condition (r= -0,246, p=0,028). Lastly contradictory is the fact that the correlation between levels of pain and QoL during treatment was positive (r=0,275, p=0,014), despite the fact that high levels of pain show good general condition (r=-0,373, p=0,001). Table 2.
Regarding the results of paired sample correlations of the scales after the appropriate treatment, they seem to be in partial correlation with the results prior to treatment. The correlation between PSQI -DS and PSQI-FSS is statistically significant (r=0,259, p=0,021 and r=0,291, p=0,009 respectively). High levels of sleepiness are associated with high levels of pain (r=0.280, p=0,012), high levels of dyspnea are correlated with increased fatigue (r=0,796, p=<0,001) and pain (r=0,281, p=0,013) and high levels of fatigue are followed by high levels of pain (r=0,380, p=<0,001) Table 3.
Pearson correlations of the examined scales before the treatment
(Author's own, 2017)
Pearson correlations of the examined scales after the treatment
(Author's own, 2017)
Observing the results that arise from the comparison of the mean scoring of the scales prior and after treatment, initially is obvious that sleep quality of patients with lung cancer is improved after treatment (p<0.001). In addition, based on the mean score of ESS scale, the degree of sleepiness is decreasing (p=0,001). In contrast, symptoms of dyspnea are more frequent (p<0,001) after treatment as the mean score of DS scale is higher after compared to prior treatment. Despite the increase on dyspnea an improvement in fatigue is observed by the end of treatment (p=0,008). In addition, levels of pain are lower after treatment in patients with cancer (p<0,001), with the estimated quality of life based on the mean score of FACT-G to be significantly improved (p<0,001). Lastly, no statistically important differentiations in patients general health status is observed before and after treatment (p=0,573) Table 4.
Paired samples t-tests of the examined scales before & after the treatment
|Before treatment||After treatment|
|Mean Scores||S.D.||Mean Scores||S.D.||t||p|
(Author's own, 2017)
Quality of life in patients with cancer and all skeletal and non-skeletal related effects is crucial in order to plan the appropriate treatment. Variables under test associated with psychological state and functionality involve pain, fatigue and sleep quality.[4-6] In this study, the results showed that patients with lung cancer fatigue before initiation of treatment had bad sleep quality, which is combined with significant dyspnea and fatigue. It has been corroborated that sleep quality in such patients is poor and associated with everyday fatigue. Moreover statistically significant correlations exist between pain and sleepiness, dyspnea and fatigue, dyspnea and pain, pain and fatigue whereas appears to be negative correlation between general state of health and fatigue. Our results showed that poor quality of life in patients with lung cancer is due to pain and fatigue. This also reflects as poor sleep quality and dyspnea, established also by other studies with cancer patients.[8, 14-16] However there is a contradiction in our findings regarding the effect of pain in quality of life which was positive. This can be attributed to methodological limitations and to the fact that quality of life is a multifaceted notion affected by a variety of parameters.
In addition, our study showed existence of statistically significant correlation amongst the above variables, after treatment initiation, pointing out the connection between poor sleep quality and dyspnea symptoms, poor sleep quality and fatigue, dyspnea and fatigue, dyspnea and pain, fatigue and pain, but also a positive correlation between sleepiness and pain. These results show the specificity and eligibility of the used scales in evaluating QoL in cancer patients. Regarding post treatment QoL, results from the FACT-G and rest of the scales showed that it was significantly improved, in accordance with previous studies on patients that were treated with chemotherapy, radiotherapy and surgery.[38-40] Also, there was improvement in sleep quality, sleepiness, fatigue and pain. Although dyspnea occurrence increased, fatigue was not affected. Previous study showed that quality of sleep is not improved with chemotherapy , which is in contradiction with our results.
The most important observation in this study is the significant improvement in QoL in patients with lung cancer, when zoledronic acid is co administered with the appropriate chemotherapy. Zoledronic acid is a bone targeting agent, with high specialization in metastatic bone pain, reducing the need of opioids.[19, 20] In this study the co administration of zoledronic acid to radiotherapy, reduced levels of pain when compared to radiotherapy and clodronic acid. This showed the importance of zoledronic acid in improving QoL. Denosumab shows high affinity and specificity against RANKL, which is important in osteoclast formation, differentiation, and survival. It is also a key activator of osteoclasts, essential for mediating bone resorption through tumor-releasing growth factors and cytokines. Increasing evidence has suggested that denosumab inhibits osteoclast-mediated bone resorption and prevents bone metastases. Zoledronic acid reduces proliferation and viability of cancer cells, adherence and filtration and reduces the secretion of metalloproteinases all of which are properties of metastatic cancer disease. Moreover bisphosphonates have anti-angiogenic effect by obstructing substances that promote angiogenesis like fibroblast growth factor. In our study we chose zoledronic acid over denosumab because of the significantly higher cost of the later. A limitation of our study is the different methods of staging between the patients, with and without bone metastases, which doesn't affect our results as we tried to examine changes in quality of life in patients with lung cancer under treatment with co administration of zoledronic acid, without taking in consideration the presence of metastatic disease. Another limitation of this study has to do with the fact that most of the questionnaires are self-administered, and partiality is inevitable. With our relatively small sample, further research with larger sample is required in order to confirm the above results.
This study was supported by Shanghai Zhangjiang Major Project (grant number ZJ2016-ZD-004).
The authors have declared that no competing interest exists.
1. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. The European respiratory journal. 1994;7:1350-64
2. Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The oncologist. 2004;9(Suppl 6):14-24 doi:10.1634/theoncologist.9-90006-14
3. Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B. et al. National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. Journal of the National Cancer Institute. 2003;95:1110-7
4. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. Journal of the National Cancer Institute Monographs. 2004:40-50 doi:10.1093/jncimonographs/lgh027
5. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psycho-oncology. 2001;10:19-28
6. Carlsen K, Jensen AB, Jacobsen E, Krasnik M, Johansen C. Psychosocial aspects of lung cancer. Lung cancer. 2005;47:293-300 doi:10.1016/j.lungcan.2004.08.002
7. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung cancer. 2001;31:233-40
8. Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M. et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. British journal of cancer. 2009;100:1566-74 doi:10.1038/sj.bjc.6605053
9. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006;12:6243s-9s doi:10.1158/1078-0432.CCR-06-0931
10. Harris K, Chow E, Zhang L, Velikova G, Bezjak A, Wu J. et al. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. European journal of cancer. 2009;45:2510-8 doi:10.1016/j.ejca.2009.05.024
11. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Annals of oncology: official journal of the European Society for Medical Oncology. 2007;18:1437-49 doi:10.1093/annonc/mdm056
12. von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L. et al. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2016;24:1327-37 doi:10.1007/s00520-015-2908-1
13. Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S. et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011;6:576-82 doi:10.1097/JTO.0b013e318206a1e3
14. Green CR, Hart-Johnson T, Loeffler DR. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer. 2011;117:1994-2003 doi:10.1002/cncr.25761
15. Ferreira VT, Dibai-Filho AV, Kelly de Oliveira A, Gomes CA, Melo ES, Maria de Almeida A. Assessing the impact of pain on the life of breast cancer survivors using the Brief Pain Inventory. Journal of physical therapy science. 2015;27:1361-3 doi:10.1589/jpts.27.1361
16. Khan L, Uy C, Nguyen J, Chow E, Zhang L, Zeng L. et al. Self-reported rates of sleep disturbance in patients with symptomatic bone metastases attending an outpatient radiotherapy clinic. Journal of palliative medicine. 2011;14:708-14 doi:10.1089/jpm.2010.0491
17. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical oncology. 2012;24:112-24 doi:10.1016/j.clon.2011.11.004
18. Arias F, Arraras JI, Asin G, Zarandona U, Mora I, Errasti M. et al. To What Extent Does Radiotherapy Improve the Quality of Life of Patients with Bone Metastasis? A Prospective, Single-Institutional Study. American journal of clinical oncology. 2015 doi:10.1097/COC.0000000000000249
19. von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2008;16:1105-15 doi:10.1007/s00520-008-0487-0
20. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, Group EGW. Management of cancer pain: ESMO Clinical Practice Guidelines. Annals of oncology: official journal of the European Society for Medical Oncology. 2012;23(Suppl 7):vii139-54 doi:10.1093/annonc/mds233
21. Wang F, Chen W, Chen H, Mo L, Jin H, Yu Z. et al. Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases. Medical oncology. 2013;30:657. doi:10.1007/s12032-013-0657-x
22. von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D. Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. European journal of cancer. 2017;71:80-94 doi:10.1016/j.ejca.2016.10.021
23. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry research. 1989;28:193-213
24. Buysse DJ, Reynolds CF 3rd, Monk TH, Hoch CC, Yeager AL, Kupfer DJ. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep. 1991;14:331-8
25. Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. Journal of pain and symptom management. 2004;27:140-8 doi:10.1016/j.jpainsymman.2003.12.002
26. Zarogoulidis P, Steiropoulos P, Perantoni E, Archontogeorgis K, Eleftheriadou E, Porpodis K. et al. Subjective sleep quality in lung cancer patients before and after chemotherapy. Thoracic cancer. 2013;4:138-42 doi:10.1111/j.1759-7714.2012.00156.x
27. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15:376-81
28. Huyett P, Kim S, Johnson JT, Soose RJ. Obstructive sleep apnea in the irradiated head and neck cancer patient. The Laryngoscope. 2017;127:2673-7 doi:10.1002/lary.26674
29. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. American journal of respiratory and critical care medicine. 1999;159:321-40 doi:10.1164/ajrccm.159.1.ats898
30. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580-6
31. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK. et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-96
32. Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2000;11:561-7
33. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Annals of the Academy of Medicine, Singapore. 1994;23:129-38
34. Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: a focused review. Indian journal of palliative care. 2011;17:108-15 doi:10.4103/0973-1075.84531
35. Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA. et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Annals of oncology: official journal of the European Society for Medical Oncology. 2011;22:2179-90 doi:10.1093/annonc/mdq721
36. EuroQol G. EuroQol-a new facility for the measurement of health-related quality of life. Health policy. 1990;16:199-208
37. Reichardt P, Leahy M, Garcia Del Muro X, Ferrari S, Martin J, Gelderblom H. et al. Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma. 2012;2012:740279. doi:10.1155/2012/740279
38. Salati M, Brunelli A, Xiume F, Refai M, Sabbatini A. Quality of life in the elderly after major lung resection for lung cancer. Interactive cardiovascular and thoracic surgery. 2009;8:79-83 doi:10.1510/icvts.2008.184986
39. Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA. et al. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2009;17:307-13 doi:10.1007/s00520-008-0489-y
40. Jain S, Poon I, Soliman H, Keller B, Kim A, Lochray F. et al. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2013;108:320-5 doi:10.1016/j.radonc.2013.06.045
41. Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I. et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015;26:2521-7 doi:10.1007/s00198-015-3174-2
Corresponding authors: Paul Zarogoulidis, MD. PhD. Senior Consultant, Pulmonary-Oncology Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece. Mobile: 00306977271974; e-mail: pzarogcom. Bai Chong, MD, Ph. D, Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China, e-mail: bc7878com.